Madrigal Pharmaceuticals (MDGL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Madrigal Pharmaceuticals (MDGL) is Neutral.

The composite score behind that read is -0.06, weighing +0.17 of bullish evidence against -0.21 bearish.

Madrigal Pharmaceuticals last closed at $471.75, -1.08% on the session.

Against the IVW growth benchmark the position is -1.88% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

7 graded predictions for MDGL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Madrigal Pharmaceuticals in the 17th percentile on return on equity, where 100 is best.

Madrigal Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $11.02B.

StockMap tracks Madrigal Pharmaceuticals as the 24th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Madrigal Pharmaceuticals ranks 161st of 381 in the group, against a group median of -0.08.